• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CLGN

    CollPlant Biotechnologies Ltd

    Subscribe to $CLGN
    $CLGN
    Industrial Specialties
    Health Care

    CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

    IPO Year:

    Exchange: NASDAQ

    Website: collplant.com

    Peers

    $BLRX
    $ELTK

    Recent Analyst Ratings for CollPlant Biotechnologies Ltd

    DatePrice TargetRatingAnalyst
    2/17/2023$22.75Buy
    Alliance Global Partners
    See more ratings

    CollPlant Biotechnologies Ltd SEC Filings

    See more
    • SEC Form F-1 filed by CollPlant Biotechnologies Ltd

      F-1 - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      6/17/25 4:16:04 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      6/9/25 7:08:40 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      6/4/25 7:10:31 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form D filed by CollPlant Biotechnologies Ltd

      D - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      6/4/25 6:21:41 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 424B5 filed by CollPlant Biotechnologies Ltd

      424B5 - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      6/2/25 9:50:16 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      6/2/25 9:45:16 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      5/30/25 7:09:50 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      5/28/25 7:43:52 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      4/15/25 8:14:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 20-F filed by CollPlant Biotechnologies Ltd

      20-F - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      3/26/25 10:13:19 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    CollPlant Biotechnologies Ltd Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on CollPlant with a new price target

      Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75

      2/17/23 8:30:35 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

      HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously

      2/9/21 6:08:53 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    CollPlant Biotechnologies Ltd Press Releases

    Fastest customizable press release news feed in the world

    See more
    • COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

      CollPlant's proprietary rhCollagen to be used in clinical and commercial applications REHOVOT, Israel, June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen)  for tissue regeneration and medical aesthetics, today announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences. The amended agreement broa

      6/9/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS

      - Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel, June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively.

      6/4/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

      REHOVOT, Israel, May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise pr

      5/30/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      - In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed -  REHOVOT, Israel, May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained discip

      5/28/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

      REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina

      5/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

      CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel, April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing i

      4/15/25 8:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp

      3/26/25 8:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

      Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:

      3/19/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

      REHOVOT, Israel, Feb. 24, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, a

      2/24/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • CollPlant Biotechnologies Provides a Corporate Update

      -  Additional patent granted for photocurable dermal filler-  Update on AbbVie dermal filler program and achievement of contingent payment-  Plan for cost reductions in place to extend cash runway REHOVOT, Israel, Feb. 12, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update.   Photocurable Dermal Filler Program: Additional Patent Grante

      2/12/25 6:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care